The abnormal activation of NF-κB contributes to significant cell proliferation and migration in CRC and in other types of cancer (3), and the inhibition of NF-κB activity has been shown to significantly reduce cancer cell growth and enhance cell apoptosis, indicating that NF-κB members are potential therapeutic targets in tumors (4). This evidence concerns the gene NFKB1 and cancer.